TGFB2 and non-small cell lung carcinoma: This pivotal discovery of the miR‐7/TGF‐β2 axis in acidic pH‐mediated lung cancer progression introduces miR‐7 as a potential therapeutic target and reliable biomarker for non‐small‐cell lung cancer (NSCLC) [92].